R-Pharm licenses Merck hepatitis C drug

Friday, July 6, 2012 03:59 PM

The Russian pharmaceutical company R-Pharm—headed by the Ministry of Industry and Trade of the Russian Federation—entered into a licensing agreement with MSD (Merck) for rights to a novel investigational, hepatitis C once-daily protease inhibitor, narlaprevir. 

The agreement provides an opportunity for R-Pharm to conduct late-stage clinical trials in Russia, which is among the goals of the Russian government's Pharma 2020 initiative. R-Pharm will gain rights to develop and commercialize narlaprevir in Russia and the Commonwealth of Independent States (CIS). R-Pharm will pay MSD (acting through a subsidiary), an upfront payment and undisclosed royalties on sales of narlaprevir. Merck has retained the right to co-promote narlaprevir in these regions and retains rights to the drug outside of Russia and the CIS countries.

Narlaprevir is a second generation NS3 serine protease inhibitor developed by MSD.  In a phase IIa clinical study, narlaprevir administration resulted in a robust decline in the level of hepatitis C virus detected in the blood and high sustained viral response rates when followed by standard of care in both treatment-experienced and treatment-naïve HCV genotype 1-infected patients.

"MSD is pleased that through this agreement, R-Pharm can pursue the development of this potentially important technology for the treatment of hepatitis C, an area of substantial unmet need in Russia," said Kevin Ali, president of emerging markets, MSD. "This unique technology transfer deal is consistent with the Russian government's desire to create a stronger local innovative pharma industry to drive economic growth in the sector. Developing narlaprevir will enable R-Pharm to gain deep experience in late stage clinical trials—the crucial phase of drug development."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs